medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (6)


Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C

Fenili ATG, Jönck SG, Lazzarotto C, Pacheco SA, Manes J, da Graça FM, Cacese SMB, Narciso-Schiavon JL, Dantas-Correa EB, de Lucca SL

Idioma: Ingles.
Referencias bibliográficas: 40
Paginas: 855-861
Archivo PDF: 125.45 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, Colombo M, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18(Suppl. 1): 1-16.

  2. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl. 1): 74-81.

  3. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.

  4. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.

  5. Ministério da Saúde. Boletim Epidemiológico das Hepatites Virais 2011. Available from: http://www.aids.gov.br/pub licacao/2011/boletim_epidemiologico_hepatites_viraiv_2011 [Accessed August 7, 2011].

  6. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, Poynard T. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44: S19-S24.

  7. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  8. Alberti A, Vario A, Ferrari A, Pistis R. Review article: chronic hepatitis C-natural history and cofactors. Aliment Pharmacol Ther 2005; 22(Suppl. 2): 74-8.

  9. Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24(Suppl. 2): 3-8.

  10. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.

  11. Al Knawy B, Shiffman M. Percutaneous liver biopsy in clinical practice. Liver Int 2007; 27: 1166-73.

  12. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-18.

  13. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-32.

  14. Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology 1988; 95: 734-9.

  15. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

  16. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, Sulkowski M, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.

  17. Gayotto LC, SBP/SBH. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. Projeto do Clube de Patologia Hepática da Sociedade Brasileira de Patologia aprovado pela Sociedade Brasileira de Hepatologia. GED 2000; 19: 137-40.

  18. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-43.

  19. Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42(Suppl.): S22-S36.

  20. Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008; 12: 883-900, x.

  21. Schiavon LL, Schiavon JL, Filho RJ, Sampaio JP, Lanzoni VP, Silva AE, Ferraz ML. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology 2007; 46: 307-14.

  22. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL, Sampaio JP, Lanzoni VP, Ferraz ML, Silva AE. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/ hepatitis C virus co-infection. Liver Int 2008; 28: 486-93.

  23. Shin WG, Park SH, Jang MK, Hahn TH, Kim JB, Lee MS, Kim DJ, et al. Aspartate aminotransferase to platelet ratio index (APRI) can predict liver fibrosis in chronic hepatitis B. Dig Liver Dis 2008; 40: 267-74.

  24. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.

  25. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-21.

  26. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, et al. Performance of the aspartate aminotransferaseto- platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.

  27. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-6.

  28. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62.

  29. Adler M, Gulbis B, Moreno C, Evrard S, Verset G, Golstein P, Frotscher B, et al. The predictive value of FIB-4 versus FibroTest, APRI, FibroIndex and Forns index to noninvasively estimate fibrosis in hepatitis C and nonhepatitis C liver diseases. Hepatology 2008; 47: 762-3.

  30. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28: 1352-62.

  31. Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, et al. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18: 746-53.

  32. Ahmad W, Ijaz B, Javed FT, Gull S, Kausar H, Sarwar MT, Asad S, et al. A comparison of four fibrosis indexes in chronic HCV: development of new fibrosis-cirrhosis index (FCI). BMC Gastroenterol 2011; 11: 44.

  33. Guzelbulut F, Cetinkaya ZA, Sezikli M, Yasar B, Ozkara S, Ovunc AO. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol 2011; 22: 279-85.

  34. Martinez SM, Fernandez-Varo G, Gonzalez P, Sampson E, Bruguera M, Navasa M, Jimenez W, et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-48.

  35. Giannini E, Botta F, Fasoli A, Ceppa P, Risso D, Lantieri PB, Celle G, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci 1999; 44: 1249-53.

  36. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24.

  37. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8.

  38. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006; 26: 1095-99.

  39. Shaikh S, Memon MS, Ghani H, Baloch GH, Jaffery M, Shaikh K. Validation of three nonivasive markers in assessing the severity of liver fibrosis in chronic hepatitis C. J Coll Physicians Surg Pak 2009; 19: 478-2.

  40. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41: 1376-82.




2020     |     www.medigraphic.com